Article Text

Download PDFPDF
Efficacy and safety of intravenous Ig and alterations in haematological parameters of infants with isoimmune haemolytic disease
  1. B Freyne1,2,
  2. F M O'Hare1,2,
  3. E J Molloy1,2,3,4
  1. 1Department of Neonatology, National Maternity Hospital, Dublin, Ireland
  2. 2UCD School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland
  3. 3Royal College of Surgeons of Ireland, Dublin, Ireland
  4. 4Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland
  1. Correspondence to Dr B Freyne, SpR Paediatrics, Department of Neonatology, National Maternity Hospital, Holles Street, Dublin 2, Ireland; bridgetfreyne{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Intravenous Ig (IVIg – polyclonal Ig) administration to neonates with Rhesus-mediated isoimmune haemolytic disease has been shown to decrease the need for exchange transfusion (number needed to treat=2.7).1 The use of IVIg as an adjuvant treatment for neonatal sepsis has been extensively studied. A 2010 Cochrane systematic review of this application in preterm (<37 weeks)/low birthweight (<2500 g) infants analysed the results of 19 studies involving 5000 infants. The authors concluded that IVIg administration resulted in a 3–4% reduction in sepsis or serious infection but was not associated with decreased …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.